×
PainReform Net Current Debt 2020-2024 | PRFX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PainReform net current debt from 2020 to 2024. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
PainReform Net Current Debt 2020-2024 | PRFX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PainReform net current debt from 2020 to 2024. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$95B
Zoetis (ZTS)
$66.3B
Takeda Pharmaceutical (TAK)
$46.8B
Daiichi Sankyo, - (DSNKY)
$41.7B
Summit Therapeutics (SMMT)
$18.2B
Sandoz Group AG (SDZNY)
$17.7B
Merck (MKKGY)
$17.2B
Astellas Pharma (ALPMY)
$16.9B
Shionogi (SGIOY)
$14.1B
United Therapeutics (UTHR)
$12.8B
Neurocrine Biosciences (NBIX)
$10B
IPSEN (IPSEY)
$8.6B
Orion OYJ (ORINY)
$8B
Madrigal Pharmaceuticals (MDGL)
$6.7B
Stevanato Group S.p.A (STVN)
$6.6B
Corcept Therapeutics (CORT)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.8B
Ono Pharmaceutical (OPHLF)
$5.5B
Grifols, S.A (GRFS)
$4.9B
Ionis Pharmaceuticals (IONS)
$4.5B
Soleno Therapeutics (SLNO)
$3.2B
Crinetics Pharmaceuticals (CRNX)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.3B
Recursion Pharmaceuticals (RXRX)
$2.2B
Hypermarcas (HYPMY)
$2.1B
NewAmsterdam Pharma (NAMS)
$1.8B
Centessa Pharmaceuticals (CNTA)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.5B